Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Assets: 2014-2025

Historic Current Assets for CytomX Therapeutics (CTMX) over the last 10 years, with Sep 2025 value amounting to $149.2 million.

  • CytomX Therapeutics' Current Assets rose 20.16% to $149.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.2 million, marking a year-over-year increase of 20.16%. This contributed to the annual value of $107.3 million for FY2024, which is 41.34% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' Current Assets is $149.2 million, which was down 9.36% from $164.6 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Current Assets registered a high of $400.0 million during Q1 2021, and its lowest value of $86.6 million during Q1 2025.
  • Over the past 3 years, CytomX Therapeutics' median Current Assets value was $164.6 million (recorded in 2025), while the average stood at $157.0 million.
  • Over the last 5 years, CytomX Therapeutics' Current Assets had its largest YoY gain of 20.16% in 2025, and its largest YoY loss of 48.20% in 2025.
  • CytomX Therapeutics' Current Assets (Quarterly) stood at $310.3 million in 2021, then fell by 23.59% to $237.1 million in 2022, then declined by 22.85% to $182.9 million in 2023, then crashed by 41.34% to $107.3 million in 2024, then rose by 20.16% to $149.2 million in 2025.
  • Its last three reported values are $149.2 million in Q3 2025, $164.6 million for Q2 2025, and $86.6 million during Q1 2025.